Aravax

About

Aravax develops PVX108, a synthetic-peptide peanut allergy therapy undergoing Phase 2 expansion and Phase 3 preparation after Phase 1 safety and immunomodulatory results.

Mission

Aravax is developing PVX108, a synthetic-peptide therapy derived from peanut allergens intended to retrain the immune system to tolerate peanuts. PVX108 was well tolerated in Phase 1 studies and produced clinically relevant changes to peanut immune responses; those results were recently published in Allergy. The company plans to expand its Phase 2 trial to the United States and accelerate preparations for a Phase 3 study. Aravax credited founders Robyn O'Hehir, Jenny Rolland and Sara Prickett, who conducted the original research at Alfred Health and Monash University, and highlighted the management team's efforts to advance development. The company announced it has closed a US$42 million Series B to fund these next clinical steps.

Quick Facts